Canada: Protecting Life Science Innovations In Canada – A Year In Review

In this article, we highlight some recent Canadian developments from last year that have particular relevance for the life sciences industry.

Legislation and Treaties

Canada has committed to a number of significant legislative changes expected to come into effect in the next few years.

Trade Treaties

The past year in Canadian life sciences has seen a lot of treaty talk. Not much action has happened yet. We are still waiting for word on if and how the newly-elected federal government will implement the Canada-Europe Free Trade Agreement. The agreement was originally reached in 2013 by a prior federal government. 

In 2015, the prior federal government agreed to the Trans-Pacific Partnership, and the newly-elected federal government said that it intends to follow through with implementation of this treaty. 

The potential for up to two years of Canadian patent term extension is the main issue that is of interest for life sciences patent owners in these two treaties. The treaties may also cause amendments to Canada's linkage regulations (generally similar to US ANDA litigation) in order to prevent a multiplicity of proceedings and to give brand name companies appeal rights comparable to those of generics. 

Patent, Design, Trademark and Plant Breeders' Rights Amendments (IP Treaties)

The plant breeders' rights (PBR) amendments came into effect in 2015, bringing many changes as Canada harmonizes its PBR system with the 1991 UPOV Treaty. For example, the term of rights was extended from 18 years to 25 years for trees and vines, with a 20 year term for all other varieties. There is a new one year grace period to file after sales in Canada, getting rid of the absolute novelty requirement (there has always been, and remains, a longer grace period for sales outside Canada). 

We are still waiting for the Canadian Intellectual Property Office (CIPO) to implement significant amendments for patents, designs and trademarks that were passed in 2014. Consultations are expected to begin late 2016. The expected dates for implementation have been pushed back to 2017-18. The patent and design amendments are not specific to life science patents. The amendments implement the Patent Law Treaty and the design Hague Treaty that will respectively impact all patents and designs. The trademark amendments will have significant impact for life science trademarks owners by implementing the Madrid Protocol, among other changes. Among the many changes, use will no longer be required for registration, so companies will have to file quickly to get ahead of competitors and trademark squatters. 

Prior Art Issues

Obvious to Try Test

A common issue that patentees address in respect of a life sciences invention is whether the invention was "obvious to try". The Federal Court of Appeal in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2015 FC 178; 2015 FCA 286 confirmed the Supreme Court of Canada's test from Apotex Inc. v. Sanofi-Synthelabo Canada Inc., 2008 SCC 61, that it must be "more or less self-evident to try to obtain the invention. Mere possibility that something might turn up is not enough". This overturned a trial Court decision that would have made it easier to challenge patents by setting the test at, "whether the skilled person had good reason to pursue predictable solutions or solutions that provide a 'fair expectation of success.'" Maintaining the "self-evident' test is significant in life sciences where slight changes or improvements can result in significant unexpected advances.

Amount of Support and Disclosure Required in Patent Application

Utility Disclosure Requirement

Also relevant to life sciences is the requirement for explicit disclosure of utility in a patent. This requirement stems from the Supreme Court of Canada's 2002 decision relating to AZT in Apotex v. Wellcome Foundation Ltd. 2002 SCC 77, which set out the requirements for a sound prediction of utility of a patent (as opposed to demonstrated utility via experiments etc.). Since then, there have been numerous decisions that question what is meant by proper disclosure for utility and when such disclosure is required. In Gilead Sciences, Inc. v. Idenix Pharmaceuticals Inc., 2015 FC 1156, the Court confirmed that for a new composition, there is no requirement to specifically disclose the utility in the application. A specific utility must, however, be disclosed in patents claiming a new use of a known compound.

Sufficiency of Disclosure Requirement

Canadian courts have also been grappling with the analysis of what is required for an application to sufficiently disclose the invention under Subsection 27(3) of the Canadian Patent Act. In this regard, Gilead, discussed above, stated that a disclosure is sufficient where common general knowledge and routine experimentation can make the invention work. However, in Gilead, even though there was evidence of a wealth of literature being available to the skilled person, the Court held that routine trial and error experimentation can become undue experimentation where there is an excess of choice. The Court ultimately found that the disclosure was not sufficient for that reason. Accordingly, caution should still be taken so that there is enough information in the patent specification such that the skilled person would not be left with an "excess of choice", particularly for important steps in the synthesis of new chemical compounds or other compositions of matter.

Subject Matter

Methods of Medical Treatment

The Federal Court provided some clarity in relation to patents directed to drug dosage claims in the late 2014 decision in AbbVie Biotechnology Ltd. v. Canada (Attorney General) 2014 FC 1251, confirming that certain claims to specific dosages or dosing schedules are patentable. This improved the landscape for dosage claims, and CIPO issued a revised practice notice taking the case into account (Revised Examination Practice Respecting Medical Uses – PN 2015-01) as well as associated examples. The new guidelines focus the analysis on whether the invention is directed at what to use for treatment, which is patentable, versus how to use for treatment, which may be unpatentable if it interferes with or requires professional skill of a physician. These new guidelines and examples provide more certainty in the prosecution of medical use inventions and should help expedite patent prosecution in this area.

Diagnostics - New Canadian Patent Office Guidance

Examination of certain life sciences diagnostic inventions were on hold as Examiners awaited further guidance. There was no Canadian court decision on diagnostic subject matter eligibility, but a business method subject matter decision influenced subject matter analysis by CIPO in other fields, such as diagnostics. A new practice notice was finally released, called Examination Practice Respecting Medical Diagnostic Methods – PN 2015-02. Examination is now ongoing for such inventions, and CIPO is parsing diagnostics claims more carefully on subject matter eligibility. We are working on strategies to address these guidelines and continue to protect diagnostic inventions. It remains to be seen how these new guidelines will affect life sciences patent applications in Canada.

We will continue to monitor the changes on the horizon in relation to the treaties and case law specific to life sciences. We will provide updates on the progress of life science inventions through the Canadian Patent Office in light of the new patent office guidelines. Stay tuned for 2016...

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Melanie Szweras
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions